Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Dose-Range, Placebo-Controlled, 12-Week Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

NCT07656727 is registered in ClinicalTrials.gov with BioAge Labs, Inc. as lead sponsor.

NCT NCT07656727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07656727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Dose-Range, Placebo-Controlled, 12-Week Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Lead sponsor
BioAge Labs, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 11, 2026
Completion date
December 31, 2026
Enrollment
160 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and cardiovascular risk